Fredun Pharmaceuticals share price
NSE: FREDUNBSE: 539730Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,368.40down ₹22.60 (1.62%)BSE ₹1,368.10
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,391.00.
52-week range of BSE trades to 23 Oct 2026
₹454.05Low, 12 Jan 2026₹1,666.35High, 8 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,313 Cr1,474th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 8.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 18.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.80
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 52,74940.2% delivered
Results
Standalone, as consolidated accounts are on record for only 2 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹228 Crup 8.24%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹13 Crup 19.00%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.8%
Revenue by year
Peak revenue ₹633 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 28 Nov | Dec 2024Filed 4 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 30 Jul | Sep 2025Filed 9 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 25 May | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 107 | 102 | 165 | 119 | 144 | 160 | 210 | 228 |
| Net profit | 4 | 5 | 7 | 7 | 10 | 10 | 11 | 13 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 4.0% | 5.2% | 4.3% | 5.7% | 6.8% | 6.6% | 5.3% | 5.8% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, The Company is in segment of manufacturing pharmaceuticals products, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 98% of 1,758 trading days since Nov 2018.
LowestHighest
Its median3.8Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.23.6
At or below today's level on 65% of 1,758 trading days since Nov 2018.
LowestHighest
Its median16.3Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 12% of 2,171 trading days over the last 10 years.
LowestHighest
Its median0.10%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +150.1% | +37.7% | +81.6% | 0.0% |
| 3 years | +29.2% | +36.5% | −5.5% | 0.1% |
| 5 years | +29.3% | +64.4% | −21.4% | 0.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 198 | 0.06% | ₹0.03 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 93 | 0.06% | ₹0.01 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Fredun Pharmaceuticals in market cap.
Fredun Pharmaceuticals is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Solara Active Pharma SciencesSOLARA | 2,951 | 79.9 | 2.1 | 14.8 | +27.3% | – | 2.7% | 6.4% | 0.00% |
 Ind-Swift LaboratoriesINDSWFTLAB | 2,848 | 49.7 | 2.1 | 40.8 | +113.3% | – | 4.5% | 2.0% | 0.00% |
 Shukra PharmaceuticalsSHUKRAPHAR | 2,834 | 78.6 | 31.5 | 58.3 | +115.0% | +256.2% | 47.2% | 47.3% | 0.02% |
 HikalHIKAL | 2,388 | – | 2.0 | 13.2 | −5.4% | −153.4% | −2.7% | 3.5% | 0.31% |
 Dishman Carbogen AmcisDCAL | 2,137 | 132.2 | 0.3 | 8.1 | +0.2% | −84.5% | 0.3% | 1.4% | 0.00% |
 Beta DrugsBETA | 2,107 | 39.0 | 4.8 | 22.2 | – | – | 16.4% | 14.2% | 0.00% |
 Indoco RemediesINDOCO | 2,091 | 371.3 | 2.2 | 18.7 | +12.1% | – | 0.6% | 1.7% | 0.09% |
 Sai ParenteralsSAIPARENT | 2,040 | – | 4.2 | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.40 a share, year to Mar 2017.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Jun 2026 | Final | ₹0.70 |
| 23 Sep 2025 | Final | ₹0.70 |
| 23 Sep 2024 | Final | ₹0.70 |
| 22 Sep 2023 | Final | ₹0.70 |
| 16 Sep 2021 | Final | ₹0.70 |
| 18 Sep 2020 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.66 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
23 Oct · Announcement under Regulation 30 (LODR)-Allotment
5 Oct · Announcement under Regulation 30 (LODR)-Allotment
5 Oct · Board meeting
3 Oct · Announcement under Regulation 30 (LODR)-Allotment
Fredun Pharmaceuticals share price by year
Each calendar year to 2025.Fredun Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 526.10 | +114.1% | 648.40 | 215.03 |
| 2024BSE close | 245.75 | −15.1% | 334.83 | 224.00 |
| 2023BSE close | 289.58 | −22.4% | 393.93 | 255.65 |
| 2022BSE close | 373.40 | +32.5% | 461.62 | 233.15 |
| 2021BSE close | 281.92 | +95.2% | 304.13 | 125.22 |
| 2020BSE close | 144.42 | +92.3% | 146.20 | 35.47 |
| 2019BSE close | 75.10 | −33.2% | 158.73 | 66.45 |
| 2018BSE close | 112.37 | +223.2% | 159.97 | 36.50 |
| 2017BSE close | 34.77 | +125.5% | 34.77 | 16.18 |
| 2016BSE close | 15.42 | – | 15.42 | 4.17 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2016 is from its first session, 28 Mar 2016.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,398.90 | 1,398.90 | 1,315.80 | 1,368.40 | 1,348.64 | 52,749 | 40.2% |
| 22 Oct 2026 | 1,353.20 | 1,400.00 | 1,353.20 | 1,391.00 | 1,380.71 | 38,003 | 47.7% |
| 21 Oct 2026 | 1,436.90 | 1,450.30 | 1,329.90 | 1,365.90 | 1,380.45 | 1,53,208 | 56.3% |
| 19 Oct 2026 | 1,461.30 | 1,482.00 | 1,406.00 | 1,438.40 | 1,443.00 | 93,163 | 51.7% |
| 16 Oct 2026 | 1,476.40 | 1,500.00 | 1,433.20 | 1,477.70 | 1,469.91 | 49,897 | 48.0% |
| 15 Oct 2026 | 1,538.30 | 1,538.30 | 1,419.00 | 1,462.10 | 1,455.37 | 1,26,807 | 46.8% |
| 14 Oct 2026 | 1,477.00 | 1,553.00 | 1,477.00 | 1,517.60 | 1,515.87 | 77,017 | 38.9% |
| 13 Oct 2026 | 1,520.00 | 1,521.10 | 1,468.10 | 1,476.50 | 1,485.82 | 1,55,669 | 45.7% |
| 12 Oct 2026 | 1,579.00 | 1,579.00 | 1,456.60 | 1,504.20 | 1,500.89 | 1,76,073 | 43.0% |
| 9 Oct 2026 | 1,560.80 | 1,638.20 | 1,517.90 | 1,552.30 | 1,580.65 | 4,50,916 | 15.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 16 Jul 2026 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Fredun Pharmaceuticals Limited
- NSE symbol
- FREDUN
- BSE code
- 539730
- ISIN
- INE194R01017
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Mar 2016
- Face value
- ₹10
- CIN
- L24239MH1987PLC043662
- Corporate identity number, the registrar of companies' code for it